Abstract
Pneumocystis jirovecii pneumonia (PJP) is an important opportunistic infection that has been increasingly reported in patients with rheumatic disease. Reported incidence among patients taking TNF inhibitors (TNFi) has varied, but has usually been low. Still, disease causes significant mortality among those affected and must be considered in patients with rheumatological disease presenting with dyspnea and cough. Diagnosis can be difficult in the non-HIV population, and our understanding of the epidemiology and natural history after exposure is changing. Trimethoprim–sulfamethoxazole is believed to be the most effective agent for treatment and prophylaxis, but is associated with significant adverse effects. Given the low incidence reported in most studies of patients on TNFi, prophylaxis is probably not beneficial for this patient population as a whole.
Original language | English (US) |
---|---|
Article number | 445 |
Journal | Current rheumatology reports |
Volume | 16 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2014 |
Externally published | Yes |
Keywords
- Autoimmune disease
- Biologicals
- PJP
- Pneumocystis jirovecii
- Prophylaxis
- TNF inhibitor
- Trimethoprim-sulfamethoxazole
ASJC Scopus subject areas
- Rheumatology